Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Fundamental Analysis
Alnylam Pharmaceuticals, Inc. (DUL.DE) shows moderate financial fundamentals with a PE ratio of 71.70, profit margin of 13.80%, and ROE of 96.66%. The company generates $4.0B in annual revenue with strong year-over-year growth of 65.19%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 75.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze DUL.DE's fundamental strength across five key dimensions:
Efficiency Score
ExcellentDUL.DE demonstrates superior asset utilization.
Valuation Score
ModerateDUL.DE shows balanced valuation metrics.
Growth Score
ModerateDUL.DE shows steady but slowing expansion.
Financial Health Score
ModerateDUL.DE shows balanced financial health with some risks.
Profitability Score
ModerateDUL.DE maintains healthy but balanced margins.
Key Financial Metrics
Is DUL.DE Expensive or Cheap?
P/E Ratio
DUL.DE trades at 71.70 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, DUL.DE's PEG of 0.01 indicates potential undervaluation.
Price to Book
The market values Alnylam Pharmaceuticals, Inc. at 36.68 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 55.70 times EBITDA. This signals the market has high growth expectations.
How Well Does DUL.DE Make Money?
Net Profit Margin
For every $100 in sales, Alnylam Pharmaceuticals, Inc. keeps $13.80 as profit after all expenses.
Operating Margin
Core operations generate 17.57 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $96.66 in profit for every $100 of shareholder equity.
ROA
Alnylam Pharmaceuticals, Inc. generates $10.72 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Alnylam Pharmaceuticals, Inc. produces operating cash flow of $711.46M, showing steady but balanced cash generation.
Free Cash Flow
Alnylam Pharmaceuticals, Inc. generates strong free cash flow of $640.04M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $4.83 in free cash annually.
FCF Yield
DUL.DE converts 1.62% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
71.70
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
36.68
vs 25 benchmark
P/S Ratio
Price to sales ratio
9.94
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.18
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.13
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.97
vs 25 benchmark
ROA
Return on assets percentage
0.11
vs 25 benchmark
ROCE
Return on capital employed
0.19
vs 25 benchmark
How DUL.DE Stacks Against Its Sector Peers
| Metric | DUL.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 71.70 | 29.94 | Worse (Expensive) |
| ROE | 96.66% | 738.00% | Weak |
| Net Margin | 13.80% | -575975.00% (disorted) | Strong |
| Debt/Equity | 1.18 | 0.44 | Weak (High Leverage) |
| Current Ratio | 3.13 | 4.49 | Strong Liquidity |
| ROA | 10.72% | -15756.00% (disorted) | Strong |
DUL.DE outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Alnylam Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
561.42%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
132.09%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
174.80%
Industry Style: Defensive, Growth, Innovation
High Growth